Featured Story | By Annalee Armstrong In a rare win for the difficult field of nonalcoholic steatohepatitis, Pfizer has been granted a fast-track ticket for two experimental therapies. read more |
| |
|---|
|
| Sponsored by: Agilex Biolabs Bioanalytical Laboratory Offers Qualified U.S. Clients a 43.5% Cash Rebate for Conducting Studies in its Australia-based FDA-Inspected Labs read more |
| |
|---|
|
|  | TREM Proteins: Emerging Targets of Immunotherapy TREM proteins are promising targets in neurodegenerative diseases, inflammatory diseases and cancers. Sino Biological has developed a panel of recombinant TREM protein and antibody reagents to support the study of the biology of this protein family. Learn more. |
Top Stories By Gabrielle Masson It’s survival of the fittest, and BridgeBio Pharma is cutting fat—shedding any and all extra costs in an attempts to stay afloat in a prolonged bear market. CEO Neil Kumar, Ph.D., hopes the industry will take notes to ultimately embolden a better biotech frontier. read more By Nick Paul Taylor There goes another one. After a who’s who of biopharmas failed the NIH’s inpatient COVID-19 study, NRx Pharmaceuticals has now flunked a related trial in severely ill patients, sending its share price down to the basement. read more By Nick Paul Taylor U.S. officials have arrested Enochian BioSciences co-founder Serhat Gümrükcü. The researcher is charged with conspiring to use interstate commerce facilities in the commission of murder-for-hire which resulted in a death. read more By Max Bayer Flagship Pioneering-run ProFound Therapeutics has unveiled with $75 million to further develop a trove of newly discovered proteins. read more By Annalee Armstrong Approval for Avadel’s narcolepsy drug has been set back to 2023 on a patent issue flagged by the FDA. read more By Max Bayer More the six months after Catalyst Biosciences put a “for sale” sign on its hemophilia program, the company is parting with the rest of its pipeline, selling off its line of preclinical-stage complement therapies to Vertex Pharmaceuticals for $60 million cash. read more By Gabrielle Masson Researchers have mapped out changes in T-cell activation—a key immune regulation process—moving the dial closer to discovering root causes of immune diseases, with big pharma GlaxoSmithKline already using the science to inform early drug discovery. read more By Natalie Missakian Janssen India is looking to the younger generation to help fight the country's TB epidemic with assistance from a famous Bollywood actress and an Indian hip-hop star. read more By Robert King CMS has announced another four states have gotten federal approval to extend Medicaid and CHIP postpartum coverage up to 12 months past birth. read more By Angus Liu A flurry of innovation in oncology has led to a record number of new cancer drugs launched globally in 2021. But spending on oncology medicines also reached to a new high. read more By Andrea Park Using PrecisionOS’ technology—which is installed on Oculus VR headsets—surgeons and OR technicians will be able to complete practice sessions using Siemens' Cios Spin machine together, giving them the chance to share their expertise with one another and improve their collaboration in the operating room. read more Resources Sponsored by: Catalent In this executive summary, we describe the benefits of controlled release, look at how to determine whether a drug is suitable for controlled release, review the application of PBPK modelling in controlled release formulation development and discuss how modified release products can be developed to deliver optimal patient outcomes. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored By Catalent: What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By Catalent: Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By Catalent: Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. | 
